Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 May-Jun;21(3):181-7.
doi: 10.1016/j.rpor.2015.12.002. Epub 2016 Feb 20.

Localized prostate cancer treated with external beam radiation therapy: Long-term outcomes at a European comprehensive cancer centre

Anna Boladeras  1 , Evelyn Martinez  1 , Ferran Ferrer  1 , Cristina Gutierrez  1 , Salvador Villa  2 , Joan Pera  1 , Ferran Guedea  1
Affiliations

Localized prostate cancer treated with external beam radiation therapy: Long-term outcomes at a European comprehensive cancer centre

Anna Boladeras et al. Rep Pract Oncol Radiother. 2016 May-Jun.

Abstract

Aims and background: To present survival and toxicity outcomes in patients with clinically localized, non-metastatic prostate cancer (PCa) treated with external beam radiotherapy (EBRT) combined with androgen deprivation therapy (ADT).

Materials and methods: Retrospective study of 849 PCa patients (pts) treated from 1996 to 2005. Until August 2000, all patients (281) were treated with conventional dose EBRT (<76 Gy); subsequent pts received ≥76 Gy (565 pts). Median age was 70 years (range, 39-82). Most pts were intermediate (353; 42.8%) or high-risk (344; 41.7%). Mean PSA was 10.1 ng/ml. Median dose to the prostate was 75 Gy. Complete ADT was administered to 525 pts (61.8%).

Results: Median follow-up was 109.6 months (range, 68.3-193.4). Overall survival (OS) was 92.5% and 81.1% at 5 and 10 years; by risk group (low, intermediate, high), 5- and 10-year OS rates were 94.3% and 85.9%, 92.3% and 79.2%, and 91.9% and 80.2% (p = 0.728). Five- and 10-year BRFS was 94.1% and 80.6% (low risk), 86.4% and 70.9% (intermediate), and 85.2% and 71.4% (high) (p = 0.0666). Toxicity included rectitis: grade 1 (G1) (277 pts; 32.6%), G2 (108; 12.7%), and G3 (20; 2.6%) and urethritis: G1 (294; 34.6%); G2 (223; 26.2%), and G3 (11; 1.3%). By dose rate (<76 Gy vs. ≥76 Gy), 5 and 10-year BRFS rates were 83.1% and 68.3% vs. 88.4% and 74.8% (p = 0.038).

Conclusions: Our results are comparable to other published series in terms of disease control and toxicity. These findings confirm the need for dose escalation to achieve better biochemical control and the benefits of ADT in high-risk PCa patients.

Keywords: High-dose; Prostate cancer; Radiation therapy; Survival rate; Toxicity.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Overall survival at 5 and 10 years by risk group.
Fig. 2
Fig. 2
Biochemical control at 5 and 10 years by risk group.
Fig. 3
Fig. 3
Biochemical control at 5 years and 10 years by dose <76 Gy vs. ≥76 Gy.
Fig. 4
Fig. 4
Biochemical control at 5 years and 10 years with and without androgen deprivation therapy.
See this image and copyright information in PMC

References

    1. Peeters S.T.H., Heemsbergen W.D., Koper P.C.M. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol. 2006;24(May (13)):1990–1996. - PubMed
    1. Dearnaley D.P., Sydes M.R., Graham J.D. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2007;8(June (6)):475–487. - PubMed
    1. Zietman A.L., Bae K., Slater J.D. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95–09. J Clin Oncol. 2010;28(March (7)):1106–1111. - PMC - PubMed
    1. Hoskin P.J., Rojas A.M., Bownes P.J., Lowe G.J., Ostler P.J., Bryant L. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol. 2012;103(May (2)):217–222. - PubMed
    1. Pistis F., Guedea F., Pera J. External beam radiotherapy plus high-dose-rate brachytherapy for treatment of locally advanced prostate cancer: the initial experience of the Catalan Institute of Oncology. Brachytherapy. 2010;9(March (1)):15–22. - PubMed